About US
Contact us
-
J&J's Stelara, playing defense in psoriasis, posts more positive Crohn's dataJohnson and Johnson's ($JNJ)Stelarais facing fierce new competition in the psoriasis arena. But the New Jersey drugmaker is looking for ways the med can make its mark in other disease areas, and it's2016/3/21
-
Senators lambaste Turing for 'unethical' price hikes at latest drug price hearingTuring Pharmaceuticalswas front and center again at a recent Senate hearing over drug price increases, and for the most part, it was the same old song and dance. The drugmaker came under fire by a bip2016/3/21
-
EU approves €10m funds for research on Zika virusThe European Commission is providing €10m in funding to support research on the Zika virus, which is currently found to be active in several parts of Latin America. In November last year, preliminary2016/3/18
-
Pharmapack 2016: Green Pharmaceutical PackagingGerresheimer has released the first eco-friendly plastic containers for pharmaceutical and cosmetic applications, BioPack. It makes an excellent substitute for traditional PE and PET because it has t2016/3/18
-
Takeda, Frazier Healthcare form new company to develop urology and gynaecology therapeuticsTakeda Pharmaceutical and Frazier Healthcare Partners have set up a new biopharmaceutical company to develop new therapeutics in urology and gynaecology. Known as Outpost Medicine, the new company ha2016/3/17
-
Pfizer's Xalkori receives FDA approval to treat ROS1-positive metastatic non-small cell lung cancerPfizer has received approval from the US Food and Drug Administration (FDA) for a supplemental new drug application (sNDA) for Xalkori (crizotinib) to treat patients with ROS1-positive metastatic non-2016/3/17
-
European Medicines Agency to start review of Gilead’s cancer medicine ZydeligThe European Commission has requested the European Medicines Agency (EMA) to start a review of Gilead Science's cancer medicine Zydelig (idelalisib), following concerns over serious adverse events in2016/3/16
-
India’s Lupin completes $880m acquisition of US firm GavisIndian drugmaker Lupin has completed the acquisition of US-based Gavis Pharmaceuticals and Novel Laboratories (Gavis) in a previously announced deal worth $880m. The move comes on the heels of Lupin2016/3/16
-
Pfizer wins stay from Indian court after regulator bans popular cough syrupsWestern drugmakers often complain about what sometimes seems like the capricious nature of Indian drug regulation. Now Pfizer ($PFE) has asked an Indian court to get involved after a regulator include2016/3/15
-
EMA puts Gilead's Zydelig under the lens after deaths crop up in trialsGilead's ($GILD)Zydelighas been working to carve out a place for itself as it battles other blood cancer heavyweights. But now, European regulators are undertaking a safety review of the med that coul2016/3/15